High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.

@article{Voskaridou2012HighCS,
  title={High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.},
  author={Ersi Voskaridou and Dimitrios Christoulas and Eleni Plata and Cornelia Bratengeier and Athanasios D Anastasilakis and Veroniki Komninaka and D Kaliontzi and Maria Gkotzamanidou and Stergios A Polyzos and Maria N Dimopoulou and Evangelos Terpos},
  journal={Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme},
  year={2012},
  volume={44 12},
  pages={909-13}
}
Osteoporosis is a severe complication of thalassemia. Sclerostin is a Wnt signaling inhibitor, which is produced by osteocytes and inhibits osteoblast function. Sclerostin is implicated in the pathogenesis of osteoporosis of different etiology. The aim of the study was to evaluate circulating sclerostin in 66 patients (median age 42 years) with thalassemia and osteoporosis who participated in a phase 2, randomized study (zoledronic acid vs. placebo) and the results were compared with those of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…